Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 435

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 435
---
 recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK” . The year-on-year

change in this item between 2023 and 2022 includes revenue of € 269 million recognized in profit or loss during 2023 (previously included in “ Customer

contract liabilities ” as of December 31, 2022 ).

(b) “Other current liabilities” mainly comprises provisions and liabilities for customer rebates and returns; provisions for discounts and rebates granted to

healthcare authorities and governmental programs (see Note D.23.); and the liability payable at each reporting date under the Monoclonal Antibody

Alliance with Regeneron.

(c) As of December 31, 2024 includes € 273 million (nominal value: € 290 million) for the current liability relating to royalties payable to Sobi on net sales of

Beyfortus (nirsevimab) in the United States (see Note C.2.) . D.20. Derivative financial instruments and market risks

The table below shows the fair value of derivative instruments as of December 31, 2024 , 2023 and 2022 :

| (€ million)              | Non-currentassets | Currentassets | Totalassets | Non-currentliabilities | Currentliabilities | Totalliabilities | Market value atDecember 31,2024 (net) | Market value atDecember 31,2023 (net) | Market value atDecember 31,2022 (net) |
| Currencyderivatives      | —                 |           217 |         217 |                      — |               -330 |             -330 |                                  -113 |                                    75 |                                   112 |
| operating                | —                 |            81 |          81 |                      — |               -111 |             -111 |                                   -30 |                                    22 |                                    22 |
| financial                | —                 |           136 |         136 |                      — |               -219 |             -219 |                                   -83 |                                    53 |                                    90 |
| Interest ratederivatives | —                 |             — |           — |                   -121 |                 -7 |             -128 |                                  -128 |                                  -165 |                                  -232 |
| Equity derivatives       | —                 |             — |           — |                      — |                    |                — |                                     — |                                     — |                                     — |
| Total                    | —                 |           217 |